Novo Nordisk A/S’s biggest shareholder is investing in a new Italian startup accelerator, part of an effort to foster early stage life science companies across Europe.

Jamey Millar, Novo Nordisk's Executive Vice President of US Operations, discussed the company's preparations for the upcoming CMS bridge program, which will impact Medicare beneficiaries' access to obesity treatments. Millar highlighted uncertainty about whether patient volume will surge immediately or gradually after the program's July 1 rollout, noting ongoing efforts to educate healthcare providers and pharmacists on patient eligibility. He speaks with Romaine Bostick & Katie Greifeld on "The Close." (Source: Bloomberg)

AI is already smart enough, but it lacks the right context to reach the level of AGI. Databricks CEO Ali Ghodsi talks about the current state of enterprise AI, how companies' databases are not built for an AI-native world, and why Databricks is not planning on going public just yet. He speaks with Ed Ludlow on "Bloomberg Tech." (Source: Bloomberg)

Novo Nordisk A/S said it had identified unauthorized access to some IT systems the drugmaker uses for its global business.

Novo Nordisk A/S’s Wegovy pill was approved in the UK, opening up the obesity market to people who are wary of taking a shot.

The new government in Novo Nordisk A/S’s home country of Denmark wants to test whether weight-loss drugs can help get more people into work, adding a new economic dimension to the debate over obesity treatments.

The new government in Novo Nordisk A/S’s home country of Denmark wants to test whether weight-loss drugs can help get more people into work, adding a new economic dimension to the debate over obesity treatments.

The new government in Novo Nordisk A/S’s home country of Denmark wants to test whether weight-loss drugs can help get more people into work, adding a new economic dimension to the debate over obesity treatments.

Denmark’s economy will expand 3.7% this year, beating previous forecasts on the back of strong export gains driven by demand for Novo Nordisk A/S products, according to Danske Bank A/S.

Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion, leveraging its obesity-fueled dominance to establish itself as a leader in other areas and become a major player in infectious diseases.  The agreements with Curevo, LimmaTech Biologics and Vaccine Company give Lilly access to novel technology and experimental immunizations for shingles, common bacterial pathogens and Epstein-Barr virus, according to a statement on Tuesday.  “These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” Dan Skovronsky, Lilly’s chief scientific and product officer, said in a statement.  Bloomberg News Health Reporter, Madison Muller, joins Paul Sweeney and Alexis Christoforous on "Bloomberg Intelligence" to analyze what's next for Eli Lilly after agreeing to buy three vaccine developers. (Source: Bloomberg)

Denmark’s economy grew for a fourth straight quarter mainly on the strength of its pharmaceuticals industry, highlighting the Nordic nation’s relative resilience as it braces for the fallout from the Iran war.

Justin Schrieber, CEO of telehealth company LifeMD, said that the main reason that Americans end up at virtual health care providers is to access GLP-1 weight loss medication, as well as other prescription medication. Schreiber said that there is still an untapped market for GLP-1 access and the next frontier of virtual access is for hormone replacement care. (Source: Bloomberg)

Novo Nordisk A/S agreed to hand over an experimental therapy for Parkinson’s disease to a Mark Zuckerberg-backed AI startup to potentially speed its development.

Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.

Technology stocks are driving rallies in global equities as a wave of blockbuster earnings and deals highlights the relentless pace of investment in artificial intelligence. Investors’ optimism was also buoyed by US President Donald Trump touting “Great Progress” toward a final peace deal with Iran. At a time when crude flows through the Strait of Hormuz remain at a near standstill, Brent slid on expectations that a settlement may be near. Bond yields fell in the US and Europe, while the dollar retreated against all major peers. The Opening Trade has everything you need to know as markets open across Europe. With analysis you won't find anywhere else, we break down the biggest stories of the day and speak to top guests who have skin in the game. Hosted by Anna Edwards, Guy Johnson and Tom Mackenzie. (Source: Bloomberg)

Novo Nordisk CEO Mike Doustdar discusses the drugmaker's Wegovy obesity pill which fueled sales in the first quarter. Novo is "very optimistic" on the medication despite competition from Eli Lilly, Doustdar tells Bloomberg Television, and the firm doesn't anticipate any price reductions. (Source: Bloomberg)

Novo Nordisk A/S said this year’s declines won’t be as bad as initially expected thanks to the new Wegovy pill, which helped fuel sales in the first quarter. For the year, the worst drop for both profit and sales will be 12%, compared with 13% earlier. Bloomberg’s Sanne Wass reports from Copenhagen.

Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company that counts Novo Nordisk Foundation as one of its biggest investors, raised $301.5 million in an upsized US initial public offering that priced at the top of a marketed range.

Denmark’s employed workforce shrank for the first time since mid-2024, as layoffs at Novo Nordisk A/S began to show up in official data.

Novo Nordisk A/S will integrate OpenAI’s artificial intelligence across the company to accelerate drug development.